Cargando…
Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is de...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808730/ https://www.ncbi.nlm.nih.gov/pubmed/20017892 http://dx.doi.org/10.1186/gm114 |
_version_ | 1782176530246402048 |
---|---|
author | Nathan, David G Orkin, Stuart H |
author_facet | Nathan, David G Orkin, Stuart H |
author_sort | Nathan, David G |
collection | PubMed |
description | The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions. |
format | Text |
id | pubmed-2808730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28087302010-12-09 Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases Nathan, David G Orkin, Stuart H Genome Med Musings The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions. BioMed Central 2009-12-09 /pmc/articles/PMC2808730/ /pubmed/20017892 http://dx.doi.org/10.1186/gm114 Text en Copyright ©2009 BioMed Central Ltd |
spellingShingle | Musings Nathan, David G Orkin, Stuart H Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases |
title | Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases |
title_full | Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases |
title_fullStr | Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases |
title_full_unstemmed | Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases |
title_short | Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases |
title_sort | musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases |
topic | Musings |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808730/ https://www.ncbi.nlm.nih.gov/pubmed/20017892 http://dx.doi.org/10.1186/gm114 |
work_keys_str_mv | AT nathandavidg musingsongenomemedicineenzymereplacementtherapyofthelysosomalstoragediseases AT orkinstuarth musingsongenomemedicineenzymereplacementtherapyofthelysosomalstoragediseases |